The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Which interventions offer best value for money in primary prevention of cardiovascular disease
Open accessAbstract
BACKGROUND: Despite many decades of declining mortality rates in the Western world, cardiovascular disease remains the leading cause of death worldwide. In this research we evaluate the optimal mix of lifestyle, pharmaceutical and population-wide interventions for primary prevention of cardiovascular disease. METHODS AND FINDINGS: In a discrete time Markov model we simulate the ischaemic heart disease and stroke outcomes and cost impacts of intervention over the lifetime of all Australian men and women, aged 35 to 84 years, who have never experienced a heart disease or stroke event. Best value for money is achieved by mandating moderate limits on salt in the manufacture of bread, margarine and cereal. A combination of diuretic, calcium channel blocker, ACE inhibitor and low-cost statin, for everyone with at least 5% five-year risk of cardiovascular disease, is also cost-effective, but lifestyle interventions aiming to change risky dietary and exercise behaviours are extremely poor value for money and have little population health benefit. CONCLUSIONS: There is huge potential for improving efficiency in cardiovascular disease prevention in Australia. A tougher approach from Government to mandating limits on salt in processed foods and reducing excessive statin prices, and a shift away from lifestyle counselling to more efficient absolute risk-based prescription of preventive drugs, could cut health care costs while improving population health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, legislation promoting a healthy lifestyle, such as reduced salt intake and smoking bans, are cost effective in preventing CVD. 18-22”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775 · cited 2×
“Newer evidence on drug efficacy [12,13], including alternative blood pressure-lowering drugs such as calcium channel blockers and ACE inhibitors, the changing price of statins [14–16], and increasing doubts about the use of aspirin in primary prevention [17,18], however, may mean that this is no longer the optimal str…”
BackgroundCardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163 · cited 1×
“We determine the probability of an event using the Framingham risk prediction equation [29].”
MethodMaking choices in health: who guide to cost-effectiveness analysis
(2004) · Revista Española de Salud Pública · doi:10.1590/s1135-57272004000300012 · Cited by 1,259
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232 · cited 2×
“Each cost is estimated as an average across the class, weighted by the mix of scripts provided in 2008 for an equivalent standard dose [38,39] (e.”
BackgroundLaw, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210 · cited 1×
“80% reduction in relative risk of stroke [13,50,51].”
BackgroundBrugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · cited 1×
“Newer evidence on drug efficacy [12,13], including alternative blood pressure-lowering drugs such as calcium channel blockers and ACE inhibitors, the changing price of statins [14–16], and increasing doubts about the use of aspirin in primary prevention [17,18], however, may mean that this is no longer the optimal str…”
BackgroundUnal, B., Critchley, J. A., & Capewell, S. (2004) · Circulation · doi:10.1161/01.cir.0000118498.35499.b2 · Cited by 739
Gold, M. R., Stevenson, D., & Fryback, D. G. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140513 · Cited by 652 · cited 1×
“these analyses, we base our results on health gain measured in DALYs, but since there is debate about when QALYs or DALYs are the superior measure [57], we also evaluate cost-effectiveness in QALYs to determine the impact (if any) of the QALY or DALY choice on cost-effectiveness results.”
Result
Research works printed but not linked: 1
- S Lim, 2005, Priority setting for the primary prevention of coronary heart disease and stroke in Australia [PhD thesis].
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Metadata
- Authors
- Cobiac, L. J., Magnus, A., Lim, S., Barendregt, J. J., Carter, R., & Vos, T.
- Affiliations
- The University of Queensland (AU)
- Deakin University (AU)
- Institute for Health Metrics and Evaluation (US)
- Corresponding author
- Cobiac, Linda J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-23
- Volume
- 7
- Issue
- 7
- Pages
- e41842
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3402472
- OpenAlex
- W2010609873
- Cited by
- 97
- References
- 60
- Citations by year
- 2025: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 8 · 2018: 5 · 2017: 16 · 2016: 14 · 2015: 11 · 2014: 11 · 2013: 7 · 2012: 3
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Griffith Research Online (submittedVersion, cc-by)
- Funders
- Medical Research Council
- National Health and Medical Research Council (351558)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- cardiovascular disease prevention, primary prevention, cost-effectiveness, statins, lifestyle intervention, ischemic heart disease, stroke, diuretics, calcium channel blockers, ACE inhibitors, health care costs, Australia
- MeSH terms
- Adult, Aged, Aged, 80 and over, Blood Pressure, Cardiovascular Diseases, Cholesterol, Cost-Benefit Analysis, Female, Humans, Life Style, Male, Middle Aged, Primary Prevention, Health Care Sector
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Which interventions offer best value for money in primary prevention of cardiovascular disease. https://app.cochat.ai/papers/10.1371/journal.pone.0041842
- The paper
- Cobiac, L. J., Magnus, A., Lim, S., Barendregt, J. J., Carter, R., & Vos, T. (2012). Which interventions offer best value for money in primary prevention of cardiovascular disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0041842
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.